Dexamethasone Sodium Phosphate 1 mg/mL Solution/ Drops — NDC 24208-720-02 (Billing 24208-0720-02)
This is a package of Dexamethasone Sodium Phosphate 1 mg/mL Solution/ Drops from Bausch & Lomb Incorporated, marketed since Jul 1996 and currently FDA-listed; retail pharmacies pay about $8.17 per mL (NADAC). It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 24208-720-02 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 24208 labeler · 720 product · 02 package
- Package marketed since
- Jul 26, 1996
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 2420872002 8
- Medicaid fills, this package
- 23,914 prescriptions in the last four reported quarters
- FDA record last changed
- Oct 8, 2026
Other active recalls for Dexamethasone Sodium Phosphate (different manufacturers) — 2 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 007899
- GCN: 33220
- GPI-14 (Medi-Span): 86300010102005
- HICL (First Databank): 002888
- AHFS class code: 52:08.08.00
- RxCUI (RxNorm): 226343
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Dexamethasone reduces the irritation, redness, burning, and swelling of eye caused by chemicals, heat, radiation, infection, allergy, or foreign bodies in the eye. It is sometimes used after eye surgery.
Read the full MedlinePlus article ↗- It's a steroid that calms inflammation and immune overreaction. Depending on the product, it treats allergic conditions, skin diseases, hormone disorders and eye conditions. Hemady...
- Follow your prescription label exactly. Tablets and liquid are swallowed, and your prescriber sets the amount based on your condition. Please don't stop suddenly after long use, be...
- Increased appetite, weight gain, trouble sleeping, mood swings, nausea and fluid retention are common. Call your doctor for signs of infection, black stools, vision changes, or sev...
- Some medicines interact with it, including certain antifungals, blood thinners, diabetes medicines, aspirin or NSAIDs, and estrogen products. Check with me before adding anything n...
Patient education
Supplement & herbal interactions
Dexamethasone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $8.175 | $40.87 / 5 ml |
| Medicaid paysCMS SDUD · 12 mo | $8.46 | $42.30 / 5 ml |
| Medicare drug plans payPart D · Q2 2026 | $8.56 | $42.79 / 5 ml |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 24208-0720-02 You're viewing this Main listing | 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER | 1996-07-26 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Dexamethasone Sodium Phosphate 1 mg/mLthis 24208-0720-02 | Bausch | 1 bottle | $8.174 | — | Availability likely | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Dexamethasone inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII F5UM2KM3W7
Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
-
UNII AYI8EX34EU
Creatinine is a chemical compound naturally found in muscle tissue. In medications, it may be used as a reference standard or marker to help measure kidney function or validate analytical testing procedures.
-
UNII 7FLD91C86K
Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII ML9LGA7468
A naturally-derived alcohol used as a preservative and fragrance in medicines. It helps prevent bacterial and fungal growth, extending the product's shelf life.
-
UNII 6OZP39ZG8H
Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
-
UNII TZX5469Z6I
Sodium bisulfite is a chemical salt used as a preservative and antioxidant in medicines. It prevents discoloration and degradation of active ingredients, especially in liquid formulations and injectables.
-
UNII 91MBZ8H3QO
Sodium borate is an inorganic salt compound used in medicines as a buffer to help maintain a stable pH level, and sometimes as a mild preservative or cleansing agent in topical formulations.
-
UNII 1Q73Q2JULR
Sodium citrate is a salt derived from citric acid. It works as a buffer to maintain the medicine's pH level and may also help improve taste or act as a preservative in the formulation.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
10 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Bausch & Lomb Incorporated labeler code 24208
- Bepreve bepotastine besilate 15 mg/mL Solution/ Drops NDC 24208-629-01
- Bepotastine Besilate 15 mg/mL Solution/ Drops NDC 24208-630-05
- Neomycin and Polymyxin B Sulfates and Hydrocortisone Neomycin Sulfate, 3.5 mg/mL; 10000 [USP'U]/mL; 10 mg/mL Solution/ Drops NDC 24208-631-10
- Neomycin and Polymyxin B Sulfates and Hydrocortisone Neomycin sulfate, Polymyxin B Sulfate 10 mg/mL; 3.5 mg/mL; 10000 [USP'U]/mL Suspension/ Drops NDC 24208-635-62
- Sulfacetamide Sodium 100 mg/mL Solution/ Drops NDC 24208-670-04
- PREDNISOLONE SODIUM PHOSPHATE 10 mg/mL Solution/ Drops NDC 24208-715-10
- Proparacaine Hydrochloride 5 mg/mL Solution/ Drops NDC 24208-730-06
- Fluorescein Sodium and Benoxinate Hydrochloride 2.6 mg/mL; 4.4 mg/mL Solution/ Drops NDC 24208-734-05
- Cyclopentolate Hydrochloride 10 mg/mL Solution/ Drops NDC 24208-735-01
- Soothe XP Preservative Free light mineral oil and 10 mg/mL; 45 mg/mL Solution/ Drops NDC 24208-742-01
- Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Neomycin sulfate, Polymyxin B Sulfate 3.5 mg/g; 10000 [USP'U]/g; 400 [USP'U]/g Ointment NDC 24208-780-55
- Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Neomycin sulfate and Polymyxin B Sulfate, 3.5 mg/g; 10000 [USP'U]/g; 400 [USP'U]/g; 10 mg/g Ointment NDC 24208-785-55
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic: Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies.
Otic: Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION The duration of treatment will vary with the type of lesion and may extend from a few days to several weeks, according to therapeutic response. Relapses, more common in chronic active lesions than in self-limited conditions, usually respond to treatment. Eye: Instill one or two drops of solution into the conjunctival sac every hour during the day and every two hours during the night as initial therapy.
When a favorable response is observed, reduce dosage to one drop every four hours. Later, further reduction in dosage to one drop three or four times daily may suffice to control symptoms. Ear: Clean the aural canal thoroughly and sponge dry.
Instill the solution directly into the aural canal. A suggested initial dosage is three or four drops two or three times a day. When a favorable response is obtained, reduce dosage gradually and eventually discontinue.
If preferred, the aural canal may be packed with a gauze wick saturated with solution. Keep the wick moist with the preparation and remove from the ear after 12 to 24 hours. Treatment may be repeated as often as necessary at the discretion of the physician.
⛔ Contraindications ▾
CONTRAINDICATIONS Epithelial herpes simplex keratitis (dendritic keratitis). Acute infectious stages of vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular or auricular structures. Hypersensitivity to any component of this product, including sulfites (see WARNINGS ). Perforation of a drum membrane.
⚠️ Warnings ▾
WARNINGS Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids.
In acute purulent conditions of the eye or ear, corticosteroids may mask infection or enhance existing infection. If these products are used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Employment of corticosteroid medication in the treatment of herpes simplex other than epithelial herpes simplex keratitis, in which it is contraindicated, requires great caution; periodic slit-lamp microscopy is essential.
This product contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Glaucoma with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, perforation of the globe. Rarely, filtering blebs have been reported when topical steroids have been used following cataract surgery. Rarely, stinging or burning may occur.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🧒 Pediatric Use ▾
Pediatric Use Safety and effectiveness in pediatric patients have not been established.
🧓 Geriatric Use ▾
Geriatric Use No overall differences in safety and effectiveness have been observed between elderly and younger patients.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Dexamethasone sodium phosphate suppresses the inflammatory response to a variety of agents and it probably delays or slows healing. No generally accepted explanation of these steroid properties has been advanced.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Dexamethasone sodium phosphate ophthalmic solution USP, 0.1% is supplied in a plastic squeeze bottle with a white cap and a controlled drop tip in the following size: 5 mL fill in a 10 mL bottle - NDC 24208-720-02 Storage: Store between 15°C to 25°C (59°F to 77°F). Keep out of reach of children. Distributed by: Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2022 Bausch & Lomb Incorporated or its affiliates Revised: August 2022 9100205 (Folded) 9100305 (Flat) donotuse
📋 Description ▾
DESCRIPTION Dexamethasone sodium phosphate ophthalmic solution is a clear, colorless to pale yellow topical steroid solution for ophthalmic or otic administration. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic. Dexamethasone is a synthetic analog of naturally occurring glucocorticoids (hydrocortisone and cortisone).
Dexamethasone sodium phosphate is a water soluble, inorganic ester of dexamethasone. It is approximately three thousand times more soluble in water at 25°C than hydrocortisone. Chemical Name: 9-fluoro-11β, 17-dihydroxy-16α-methyl-21-[phosphonooxy]pregna-1,4-diene-3, 20-dione disodium salt.
Each mL contains: Active: dexamethasone sodium phosphate [equivalent to 1 mg (0.1%) dexamethasone phosphate]. Inactives: sodium citrate, sodium borate, creatinine, polysorbate 80, edetate disodium dihydrate, purified water. Hydrochloric acid may be added to adjust pH (6.6-7.8).
Preservatives: sodium bisulfite 0.1%, phenylethyl alcohol 0.25%, benzalkonium chloride 0.02%. chemicalinfo
💬 Information for Patients ▾
Information for Patients Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions (see PRECAUTIONS, General ).
Patients should also be advised that if they develop an intercurrent ocular condition (e.g., trauma, ocular surgery or infection), they should immediately seek their physician’s advice concerning the continued use of the present multidose container. One of the preservatives in dexamethasone sodium phosphate ophthalmic solution, benzalkonium chloride, may be absorbed by soft contact lenses. Patients wearing soft contact lenses should be instructed to wait at least 15 minutes after instilling dexamethasone sodium phosphate ophthalmic solution before they insert their lenses.
🍼 Nursing Mothers ▾
Nursing Mothers Topically applied steroids are absorbed systemically. Therefore, because of the potential for serious adverse reactions in nursing infants from dexamethasone sodium phosphate, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of dexamethasone sodium phosphate ophthalmic solution.
📄 Package Label / Principal Display Panel ▾
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-720-02 Dexamethasone Sodium Phosphate Ophthalmic Solution, USP 0.1% (Equivalent to 0.1% Dexamethasone Phosphate) (Sterile) FOR TOPICAL APPLICATION IN THE EYE OR EAR Rx only 5 mL BAUSCH + LOMB 9564202 AB04407 carton